ATX-304
ATX-304 (O-304), pan-AMPK activator
Also known as: O-304, O304
An oral AMPK activator with one 28-day human pilot in type 2 diabetes and recent mouse data, now sold as a research chemical and promoted as an exercise mimetic or metformin replacement.
Overview
ATX-304 keeps AMPK switched on by blocking its dephosphorylation rather than by draining cellular energy. A 28-day Phase 2a in people with type 2 diabetes already on metformin improved glucose handling and microvascular blood flow, and 2025 mouse work showed benefits in fatty liver and oxidative stress. Beyond that there is no efficacy trial, no published half-life and no long-term safety data. Its 2026 popularity followed an influencer write-up and a vendor catalog launch.
Mechanism of action
Pan-AMPK activation via inhibition of PP2C-mediated dephosphorylation at Thr172, with mild mitochondrial uncoupling.
Key studies & citations
- Human2018
The AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients
28-day Phase 2a signal on glucose and perfusion.
JCI Insight - Animal2025
O304 in metabolic dysfunction-associated steatotic liver disease models
Reduced liver fat and oxidative stress in mice.
JCI Insight
Frequently asked questions
Is ATX-304 better than metformin?
There is no comparison. Its only human data is a 28-day pilot in people who were also taking metformin.